Click Therapeutics is developing digital therapeutics for depression, insomnia and other conditions. It plans to use the funds to commercialize its therapeutics, through partnerships with pharmaceutical companies including Otsuka.
Private equity firm Accelmed recently closed an oversubscribed, $400 million fund. The firm primarily invests in health-tech startups, such as its recent investment in medication adherence company MedMinder.
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases